Zylox-Tonbridge Medical Technology Co., Ltd. Class H (818) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

818 Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Zylox-Tonbridge

Medical Technology Co., Ltd. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

818 Stock 12 Month Forecast

Average Price Target

€3.52

▲(45.45% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Zylox-Tonbridge Medical Technology Co., Ltd. Class H in the last 3 months. The average price target is €3.52 with a high forecast of €3.98 and a low forecast of €3.06. The average price target represents a 45.45% change from the last price of €2.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","4":"€4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.9835068,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€3.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.064236,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.7064236,2.8128472,2.9192708,3.0256944,3.132118,3.2385416,3.3449652,3.4513888,3.5578124,3.664236,3.7706596,3.8770832,{"y":3.9835068,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.670769230769231,2.7415384615384615,2.8123076923076926,2.8830769230769233,2.953846153846154,3.0246153846153847,3.0953846153846154,3.166153846153846,3.236923076923077,3.3076923076923075,3.3784615384615386,3.4492307692307693,{"y":3.52,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.6357104615384617,2.6714209230769232,2.707131384615385,2.7428418461538464,2.778552307692308,2.814262769230769,2.8499732307692307,2.8856836923076923,2.921394153846154,2.9571046153846154,2.992815076923077,3.0285255384615386,{"y":3.064236,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.2,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.2,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.2,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.2,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.2,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.2,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€3.98

Average Price Target€3.52

Lowest Price Target€3.06

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

€3.98

Buy

64.61%

Upside

Reiterated

11/28/25

Guotai Haitong Remains a Buy on Zylox-Tonbridge Medical Technology Co., Ltd. Class H (818)

Alexis Yan

Morgan Stanley

€2.95→€3.06

Buy

26.62%

Upside

Reiterated

10/09/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

€3.06

Buy

26.62%

Upside

Reiterated

09/02/25

Unknown Analyst

CICC

Not Ranked

CICC

€3.28

Buy

35.67%

Upside

Reiterated

08/21/25

Unknown Analyst

SPDB

Not Ranked

SPDB

€3.28

Buy

35.67%

Upside

Reiterated

08/20/25

Unknown Analyst

GF Securities

Not Ranked

GF Securities

€1.95

Buy

-19.60%

Downside

Reiterated

12/29/24

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

€3.98

Buy

64.61%

Upside

Reiterated

11/28/25

Guotai Haitong Remains a Buy on Zylox-Tonbridge Medical Technology Co., Ltd. Class H (818)

Alexis Yan

Morgan Stanley

€2.95→€3.06

Buy

26.62%

Upside

Reiterated

10/09/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

€3.06

Buy

26.62%

Upside

Reiterated

09/02/25

Unknown Analyst

CICC

Not Ranked

CICC

€3.28

Buy

35.67%

Upside

Reiterated

08/21/25

Unknown Analyst

SPDB

Not Ranked

SPDB

€3.28

Buy

35.67%

Upside

Reiterated

08/20/25

Unknown Analyst

GF Securities

Not Ranked

GF Securities

€1.95

Buy

-19.60%

Downside

Reiterated

12/29/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zylox-Tonbridge Medical Technology Co., Ltd. Class H

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+3.33%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.33% per trade.

3 Months

xxx

Success Rate

2/3 ratings generated profit

Average Return

+6.60%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.60% per trade.

1 Year

Alexis YanMorgan Stanley

Success Rate

1/3 ratings generated profit

Average Return

+7.00%

reiterated a buy rating 2 months ago

Copying Alexis Yan's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +7.00% per trade.

2 Years

xxx

Success Rate

1/3 ratings generated profit

Average Return

+9.67%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +9.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

818 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 818 has received 3 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 818 average Analyst price target in the past 3 months is 3.52.

Each month's total comprises the sum of three months' worth of ratings.

818 Financial Forecast

818 Earnings Forecast

The previous quarter’s earnings for 818 were €0.04.

818 Sales Forecast

The previous quarter’s earnings for 818 were €56.82M.

818 Stock Forecast FAQ

What is DE:818’s average 12-month price target, according to analysts?

Based on analyst ratings, Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s 12-month average price target is 3.52.

What is DE:818’s upside potential, based on the analysts’ average price target?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H has 45.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Zylox-Tonbridge Medical Technology Co., Ltd. Class H a Buy, Sell or Hold?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s share price target?

The average share price target for Zylox-Tonbridge Medical Technology Co., Ltd. Class H is 3.52. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €3.98 ,and the lowest forecast is €3.06. The average share price target represents 45.45% Increase from the current price of €2.42.

What do analysts say about Zylox-Tonbridge Medical Technology Co., Ltd. Class H?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Zylox-Tonbridge Medical Technology Co., Ltd. Class H?

To buy shares of DE:818, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H (818) Stock Forecast & Price Target

818 Analyst Ratings

818 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zylox-Tonbridge Medical Technology Co., Ltd. Class H

818 Analyst Recommendation Trends

818 Financial Forecast

818 Earnings Forecast

818 Sales Forecast

818 Stock Forecast FAQ

Detailed List of Analyst Forecasts